High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group.
Ira J. Dunkel(Memorial Sloan Kettering Cancer Center), Jonathan L. Finlay(The Ohio State University), Leonard S. Sender(University of Iowa), Marc K. Rosenblum(Memorial Sloan Kettering Cancer Center), Stewart Goldman(St Nicholas Hospital), Jeffrey C. Allen(Eglin Air Force Base), James H. Garvin(Columbia University Irving Medical Center), Hao Li(China Rehabilitation Research Center), James M. Boyett(University of Illinois Chicago), Bruce Bostrom(Minnesota West Community & Technical College), A. J. Yates(Memorial Sloan Kettering Cancer Center), Sharon L. Gardner(NYU Langone Health)
Cited by 188
Related Papers
Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy
|Journal of neurosurgery|1994|508
Conventional Compared with Individualized Chemotherapy for Childhood Acute Lymphoblastic Leukemia
|New England Journal of Medicine|1998|501
Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia
|Blood|2000|475
Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas
|Cancer Cell|2020|470